翎泰天润完成近亿元Pre-A轮融资，由磐霖资本和杏泽资本联合领投

Core Insights - LyncBio Therapeutics, a company focused on innovative drug development for autoimmune diseases and tumors, successfully completed nearly 100 million RMB in Pre-A round financing [1] - The financing was led by Panlin Capital and Xingze Capital, with continued support from angel round investors [1] - The funds will primarily be used to advance clinical trials for the company's core products and expand its pipeline, supporting its innovation strategy [1] - Prior to this round, LyncBio had completed a seed round financing of several tens of millions of RMB, led by Xingze Capital [1]